Ticker: TSX – TOS
Shares Outstanding: 73,399,656
QUÉBEC CITY, Jan. 28, 2015 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, announced today that the Company will hold a conference call to update shareholders and interested parties on recent activities, following the receipt of US clearance for its new sterilization system in late December 2014.
Mr. R.M. (Ric) Rumble, President and CEO, will host the call and address topics including but not limited to:
- The claims cleared for use in the US market and their superiority over predicate devices;
- New and expected additions to the team in order to support commercial activities;
- Current marketing initiatives, status of sales channel discussions and expectations for the future;
The Conference Call will be held on Thursday, January 29, 2015 at 10:00 A.M. (EST).
Analysts and Institutional Investors are invited to participate in the call. The numbers to dial for access are 514 807-9895 (Montréal area), 647 427-7450 (Toronto area) or the Toll-Free number 1 888 231-8191. Please dial-in with the following identification number to join the conference call: 75500557
Other interested parties may listen to the live Webcast of the Conference Call accessible via CNW's Website at:
The Webcast will be archived for 90 days.
About the STERIZONE® VP4 low temperature Sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for cost effective error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75-lbs load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
Founded in 1998, TSO3's activities encompass research, development, commercialization and licensing of sterilization processes for heat-sensitive medical devices, related equipment, accessories and consumable supplies. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: R.M. (Ric) Rumble, President and CEO, (418) 651-0003, Email: [email protected]